Drug Topics
SEPTEMBER 22, 2024
In case you missed it, this week we had news about end-of-year PBM reform on the horizons, cebranopadol as a transformational new pain therapy, success in co-administration of RSV and shingles vaccines, and more.
Pharmacy Times
SEPTEMBER 22, 2024
The researchers estimate that pregnancy losses because of malaria and parasitemia risk before conception was reduced by 65% to 86%.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
SEPTEMBER 22, 2024
FTC lawsuit accuses top three PBMs of using a perverse drug rebate system to artificially inflate the price of insulin products and their profits
Med Ed 101
SEPTEMBER 22, 2024
Fluctuations in blood sugars can be very distressing for patients. This is especially true in patients who have adequate control of their diabetes. Adverse effects can lead to an escalation of diabetes medication. I’ll share my top 5 drugs that cause hyperglycemia and ultimately contribute to the prescribing cascade. Corticosteroids The first medication I have […] The post Top 5 Drugs That Cause Hyperglycemia appeared first on Med Ed 101.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The FDA Law Blog
SEPTEMBER 22, 2024
By Steven J. Gonzalez & Lisa M. Baumhardt, Senior Medical Device Regulation Expert — On August 22, 2024, FDA hosted a webinar to provide further guidance on the regulatory requirements it intends to apply to Laboratory Developed Test (LDT) developers in Stage 1 of the phaseout policy of the LDT Final Rule – during which FDA has said laboratories developing LDTs will need to comply with Medical Device Reporting (MDR) (21 CFR Part 803), Corrections and Removals (21 CFR Part 806), and Complaint
Expert insights. Personalized for you.
468 
Let's personalize your content